One century of allergen-specific immunotherapy for respiratory allergy

Immunotherapy ◽  
2011 ◽  
Vol 3 (5) ◽  
pp. 629-635 ◽  
Author(s):  
Cristoforo Incorvaia ◽  
Franco Frati
Keyword(s):  
Specific Immunotherapy ◽  
Respiratory Allergy ◽  
Allergen Specific Immunotherapy

Allergen-Specific Immunotherapy for Respiratory Allergy in Children: Unmet Needs and Future Goals

2017 ◽  
Vol 5 (4) ◽  
pp. 946-950 ◽  
Author(s):  
Pasquale Comberiati ◽  
Gian Luigi Marseglia ◽  
Salvatore Barberi ◽  
Giovanni Passalacqua ◽  
Diego G. Peroni
Keyword(s):  
Specific Immunotherapy ◽  
Unmet Needs ◽  
Respiratory Allergy ◽  
Allergen Specific Immunotherapy ◽  
Future Goals

scholarly journals Evaluation Of Clinical Changes In Pediatric Patients With Atopic Dermatitis And Respiratory Allergy Receiving Allergen-specific Immunotherapy

2019 ◽  
Vol 143 (2) ◽  
pp. AB61
Author(s):  
Cindy Elizabeth de Lira-Quezada ◽  
Alfredo Arias Cruz ◽  
Sandra N. González Diaz ◽  
David Eugenio Roman Canamar ◽  
Rosalaura Villarreal Gonzalez ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pediatric Patients ◽  
Specific Immunotherapy ◽  
Respiratory Allergy ◽  
Allergen Specific Immunotherapy ◽  
Clinical Changes

scholarly journals CLINICAL EFFICACY OF SUBLINGUAL ALLERGEN IMMUNOTHERAPY WITH ANTIPOLLIN MIXED WEEDS IN ADULTS

2016 ◽  
Vol 13 (4-5) ◽  
pp. 68-71
Author(s):  
E F Glushkova ◽  
O I Sidorovich
Keyword(s):  
Visual Analogue Scale ◽  
Asthma Control ◽  
Clinical Efficacy ◽  
Analogue Scale ◽  
Allergen Immunotherapy ◽  
Specific Immunotherapy ◽  
Nasal Congestion ◽  
Respiratory Allergy ◽  
Asthma Control Questionnaire ◽  
Allergen Specific Immunotherapy

Background. To evaluate the effectiveness of one course of sublingual allergen-specific immunotherapy (sASIT) in adults with allergy to wormwood and goose-foot pollen. Materials and methods. 28 adults aged between 20 and 53 years old with various forms of respiratory allergy were included in the study. All of them received sASIT with Antipollin Mixed weeds. The effectiveness of treatment was assessed using a visual analogue scale of rhinoconjunctivitis symptoms and Asthma Control Questionnaire. Results. As a result of sASIT a 61,6% of rhinorrhea, a 61,6% of nasal congestion , a 71,43% of nasal itching, and 82% of eyes itching reduction was shown as well as asthma control was achieved in 83,3% of patients.

scholarly journals AB0512 ALLERGIC PROFILE AND ALLERGEN-SPECIFIC IMMUNOTHERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A SINGLE CENTER OBSERVATIONAL STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1553.1-1554
Author(s):  
L. Moroni ◽  
A. Cariddi ◽  
S. Sartorelli ◽  
E. Della Torre ◽  
T. Germanò ◽  
...  
Keyword(s):  
Drug Allergy ◽  
Granulomatosis With Polyangiitis ◽  
Specific Immunotherapy ◽  
Respiratory Allergy ◽  
Age At Diagnosis ◽  
Medium Size ◽  
Eosinophilic Granulomatosis With Polyangiitis ◽  
Allergen Specific Immunotherapy ◽  
Eosinophilic Granulomatosis ◽  
Churg Strauss

Background:Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a systemic disease characterized by late onset asthma associated with small- and/or medium-size vessel vasculitis, besides eosinophil-mediated cytotoxic organ damage. About 20-30% of patients with EGPA displays allergic manifestations related with inhalant sensitization, while prevalence of food and drug allergy is unknown in this context. Moreover, some authors in the past hypothesized in favor of a possible role of allergen-specific immunotherapy (ASIT) as a trigger of disease.Objectives:Aim of the present study is to establish the prevalence of each category allergen sensitization and to determine whether atopy or specific immunotherapy could influence clinical expression of the disease.Methods:Our study consisted in a retrospective demographic and clinical data collection regarding EGPA history (including age at diagnosis, organ and tissue involvement, autoantibody profile) and the presence of allergic comorbidities or previous drug hypersensitivity reactions. Patients without either proven allergic reactions or positive tests have been excluded.Results:Fifty-three (53) patients with definitive diagnosis of EGPA have been included in the analysis among which 25 (47.2%) with chronic respiratory allergy or previous acute allergic reaction. Among allergic patients 15 (60%) resulted sensitized towards inhalants and among them 13 (86.7%) displayed multiple sensitization. Drug allergy affected 13 patients (52%), food 4 (16%). Among 15 patients with respiratory allergy, 13 were eligible to allergen-specific immunotherapy (ASIT). Seven (7) subjects underwent ASIT prior EGPA diagnosis with an average time-to-EGPA of 16.2 years. No statistically significant difference was found in terms of sex, age at diagnosis, positivity for or specificity of anti-neutrophil cytoplasm antibodies (ANCA), eosinophil count at onset, pattern of clinical manifestations comparing allergic vs. non-allergic, ASIT vs. non-ASIT, ASIT vs. allergic, ASIT vs. eligible.Conclusion:Among patients with EGPA allergies are highly prevalent, particularly towards inhalants and drugs. In the great majority of patients multiple sensitization profile is found. Atopy doesn’t seem to be associated with specific patterns of disease presentation. The absence of correlation between inhalant ASIT exposure and variation in mode and time of EGPA onset doesn’t support the hypothesis of a its potential role in triggering the disease.References:[1]Berti A et al. Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respiratory Medicine 2018; DOI: 10.1016/j.rmed.2018.07.017[2]Cottin V et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). European Respiratory Journal 2016; DOI: 10.1183/13993003.00097-2016Disclosure of Interests:Luca Moroni: None declared, adriana cariddi: None declared, Silvia Sartorelli: None declared, Emanuel Della Torre: None declared, Tommaso Germanò: None declared, Giuseppe Alvise Ramirez: None declared, Enrica Bozzolo: None declared, Mona-Rita Yacoub: None declared, Lorenzo Dagna Grant/research support from: The Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) received unresctricted research/educational grants from Abbvie, Bristol-Myers Squibb, Celgene, Janssen, Merk Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI., Consultant of: Prof Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI.

scholarly journals FoxP3 Tregs Response to Sublingual Allergen Specific Immunotherapy in Children Depends on the Manifestation of Allergy

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Anna Stelmaszczyk-Emmel ◽  
Anna Zawadzka-Krajewska ◽  
Eliza Głodkowska-Mrówka ◽  
Urszula Demkow
Keyword(s):  
Specific Immunotherapy ◽  
Clinical Manifestations ◽  
Specific Treatment ◽  
Relative Number ◽  
Allergic Diseases ◽  
Respiratory Allergy ◽  
Allergen Specific Immunotherapy ◽  
Major Health Problem ◽  
Major Health ◽  
Forkhead Box

Over the last decades allergic diseases has become a major health problem worldwide. The only specific treatment to date is allergen specific immunotherapy (ASIT). Although it was shown that ASIT generates allergen-tolerant T cells, detailed mechanism underlying its activity is still unclear and there is no reliable method to monitor its effectiveness. The aim of our study was to evaluate ASIT influence on the frequency of forkhead box P3 (FoxP3) Tregs in allergic children with various clinical manifestations. The relative number of FoxP3 Tregs in 32 blood samples from allergic children at baseline and/or after 1 year of ASIT was assessed by flow cytometry. In the entire studied group, the percentage of FoxP3 Tregs did not increase 1 year after ASIT. Nevertheless, the percentage of FoxP3 Tregs after ASIT significantly increased in children with respiratory allergy (conjunctivitis, asthma, and rhinitis) coexisting with nonrespiratory manifestations (food allergy and/or atopic dermatitis), whereas, in patients with respiratory allergy only, the percentage of FoxP3 Tregs decreased. To the best of our knowledge, this is the first report showing various differential FoxP3 Tregs response to ASIT in allergic children. FoxP3 Tregs number could be useful in treatment monitoring. Further studies are warranted to confirm these observations.

Sign in / Sign up

Export Citation Format

Share Document